Skip to content
PeptideFactSheets

Peptide · Fact sheet

Tesamorelin

Also known as Egrifta SV

Tesamorelin has a specific FDA-approved use in adults with HIV and lipodystrophy. That narrow approval should not be stretched into a general anti-aging, bodybuilding, or weight-loss claim.

FDA approved for specific usesStrong human evidence for approved uses
Weight & metabolismMuscle & recoveryHormones & sexual health

What is Tesamorelin?

Tesamorelin is a manufactured analog of growth hormone-releasing factor. It signals the pituitary gland and affects the growth-hormone pathway.

Its approved use addresses excess abdominal fat associated with HIV lipodystrophy in adults.

Benefits people look for

People sometimes encounter tesamorelin in discussions of body composition, growth hormone, or aging.

Those discussions often omit that FDA approval is limited to a defined HIV-related condition and that the label says it is not indicated for weight-loss management.

What the evidence supports

  • Clinical trials support reduction in visceral abdominal fat for the labeled population.
  • That outcome does not establish broad weight-loss, longevity, or performance benefits.
All research areas
  • HIV-associated lipodystrophy
  • Visceral abdominal fat
  • Metabolic measures
  • Other metabolic or liver outcomes studied in defined research settings

Anecdotal reports & lived experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.

No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.

We do not fill this gap with unsourced testimonials or estimated success rates.

Side effects & risks

  • The label includes contraindications and warnings involving malignancy, pregnancy, elevated IGF-1, glucose intolerance or diabetes, hypersensitivity, and fluid retention.
  • Injection-site reactions and musculoskeletal symptoms may occur.
  • Effects of long-term treatment on cardiovascular safety have not been established in the label.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research: how strong is it?

Strong human evidence for approved uses

Randomized trials support the narrow approved indication. Evidence for unrelated wellness goals is not equivalent.

Selected research to read

FDA approval & research status

Egrifta SV is FDA approved to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not indicated for general weight-loss management.

Approved uses covered here

  • Reduction of excess abdominal fat in adults with HIV and lipodystrophy

FDA approved for a narrow HIV-related use

Tesamorelin's approval is tied to the Egrifta label and HIV-associated lipodystrophy. It should not be generalized to ordinary weight loss or anti-aging claims.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What we still don’t know

  • Long-term cardiovascular outcomes
  • Benefits and harms for people outside the approved population
  • Whether changes in abdominal fat translate to every outcome a reader may care about

The takeaway

Tesamorelin is a real approved medicine with a narrow use. Its approval is not evidence for general weight loss, anti-aging, or athletic-performance claims.

Sources & further reading

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. 1
    fdaFDA prescribing information: Egrifta SV

    Official label describing indication, limitations, and safety information.

  2. 2
    clinical trialsClinicalTrials.gov: TH9507 in HIV-associated lipodystrophy

    Registry record for a Phase 3 tesamorelin study in HIV-associated lipodystrophy.

  3. 3
    clinical trialsClinicalTrials.gov: TH9507 extension study

    Registry record for a tesamorelin extension study in HIV-associated lipodystrophy.

  4. 4
    pubmedTesamorelin pooled Phase 3 analysis

    Peer-reviewed report of tesamorelin trial findings in HIV-associated lipodystrophy.

How we assess sources · Suggest a correction